Cullinan Therapeutics, Inc.

For the period ended Sep 30, 2026. Filed Nov 10, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 10, 2026

CGEM$11.23-4.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Operations and Comprehensive Income (Loss)

(in thousands, except per share amounts)

	Three Months Ended September 30,		Nine Months Ended September 30,
	2026	2025	2026	2025
Operating expenses:
Research and development	$40,169	$41,968	$126,729	$144,457
General and administrative	12,431	13,627	36,822	41,932
Total operating expenses	52,600	55,595	163,551	186,389
Loss from operations	(52,600)	(55,595)	(163,551)	(186,389)
Other income (expense):
Interest income	3,288	5,093	11,034	17,597
Other expense, net	(76)	(108)	(236)	(374)
Total other income	3,212	4,985	10,798	17,223
Net loss	$(49,388)	$(50,610)	$(152,753)	$(169,166)
Comprehensive income (loss):
Net loss	$(49,388)	$(50,610)	$(152,753)	$(169,166)
Unrealized gain (loss) on investments	(518)	366	(1,672)	1,106
Comprehensive loss	$(49,906)	$(50,244)	$(154,425)	$(168,060)
Basic and diluted net loss per share:
Common stock	$(0.74)	$(0.77)	$(2.31)	$(2.58)
Preferred stock	$(7.43)	$(7.72)	$(23.06)	$(25.84)
Weighted-average shares used in computing basic and diluted net loss per share:
Common stock	64,400	59,075	62,130	58,999
Preferred stock	204	648	411	648

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.